Adaptable Opioid Antagonist Delivery Systems for Specialized Environments

Publication ID: 24-11857547_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptable Opioid Antagonist Delivery Systems for Specialized Environments,” Published Technical Disclosure No. 24-11857547_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857547_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,547.

Summary of the Inventive Concept

The present inventive concept relates to specialized variations of opioid antagonist delivery systems, tailored to address specific operational environments, such as high-security needs, disaster relief, extreme weather conditions, and remote areas.

Background and Problem Solved

The original patent disclosed compositions and methods for opioid antagonist delivery, providing a solution for rescuing a subject from an opioid overdose. However, these solutions may not be suitable for specific, narrow market segments or unique operational environments. The present inventive concept addresses this limitation by adapting the opioid antagonist delivery system for these specialized environments, ensuring effective and timely rescue in diverse scenarios.

Detailed Description of the Inventive Concept

The inventive concept comprises a range of adaptations to the original opioid antagonist delivery system, including portable, tamper-evident containers for high-security environments; formulations and administration methods tailored for disaster relief settings; and specialized packaging and delivery systems for extreme weather conditions and remote areas. These adaptations enable the effective delivery of opioid antagonists in a variety of challenging environments, ensuring timely rescue and treatment.

Novelty and Inventive Step

The present inventive concept introduces novel adaptations to the original opioid antagonist delivery system, providing a non-obvious solution for addressing specific operational environments. The combination of portable containers, specialized formulations, and tailored administration methods constitutes a new and inventive approach to opioid antagonist delivery.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include variations in container design, formulation composition, and administration methods. For example, the use of biodegradable materials for containers, or the incorporation of additional therapeutic agents to address co-occurring conditions. These variations ensure broad conceptual coverage and adaptability to diverse operational environments.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of emergency response, disaster relief, and specialized healthcare services. The targeted market segments include government agencies, non-profit organizations, and private companies operating in high-security, disaster relief, and remote areas.

Field of Art

Pharmaceutical formulations, specifically opioid antagonist delivery systems, with expertise in parenteral drug delivery, pharmacokinetics, and medical emergency interventions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or pharmacologist with advanced degree, experience in drug formulation, understanding of parenteral delivery techniques, knowledge of adjuvant interactions, and familiarity with specialized medical environments

Obviousness Rationale

A PHOSITA would recognize that adapting the nalmefene parenteral formulation to specialized environments represents predictable variations using known pharmaceutical engineering techniques. The core pharmacological mechanism remains consistent across the disclosed variations, with container and delivery method modifications being routine design choices. The source patent's fundamental formulation provides a clear technical foundation that enables straightforward adaptation to different operational contexts.

Obvious Combinations & Variations

Source Patent Element
Parenteral formulation with nalmefene and magnesium chloride adjuvant
PTD Variation
Adapting formulation for high-security, disaster relief, and remote area delivery systems
Obviousness Reasoning
Modifying container design and packaging for specific environments represents a predictable application of known pharmaceutical delivery principles, with no substantive alteration to the core drug formulation
Source Patent Element
Intramuscular injection method with rapid plasma concentration profile
PTD Variation
Incorporating satellite communication and specialized packaging for remote area delivery
Obviousness Reasoning
Adding communication technology to an existing medical delivery system is a routine engineering adaptation that a PHOSITA would find obvious for improving operational effectiveness
Source Patent Element
Aqueous solution of nalmefene with parenterally acceptable adjuvant
PTD Variation
Exploring alternative container materials like biodegradable substances
Obviousness Reasoning
Selecting alternative container materials is a standard design choice driven by environmental or logistical considerations, representing an obvious variation to a skilled practitioner
Source Patent Element
Pharmaceutical composition for overdose rescue
PTD Variation
Tailoring delivery for high-altitude or extreme weather environments
Obviousness Reasoning
Adjusting pharmaceutical delivery for environmental constraints is a predictable engineering task that would be obvious to a PHOSITA familiar with drug stability and administration challenges
Source Patent Element
Nalmefene hydrochloride formulation with specific plasma concentration characteristics
PTD Variation
Incorporating additional therapeutic agents for co-occurring conditions
Obviousness Reasoning
Combining complementary therapeutic agents is a standard pharmaceutical development approach that would be obvious to a skilled practitioner seeking enhanced treatment efficacy
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857547, the variations disclosed herein represent obvious extensions of the original opioid antagonist delivery system, demonstrating that a Person Having Ordinary Skill In The Art would find the claimed adaptations predictable and lacking inventive step. The technical modifications to container design, delivery method, and environmental adaptation constitute routine pharmaceutical engineering practices that do not rise to the level of non-obvious innovation.

Original Patent Information

Patent NumberUS 11,857,547
TitleCompositions and methods for opioid antagonist delivery
Assignee(s)Purdue Pharma L.P.